Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06099795 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2

Study acronym: eBAM_CoV
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jun 2026 to Dec 2027 Study sites revised (2)v3 Show 1 more changeShow less
    • Study sites revised (2)

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Jun 2025 to Jun 2026 · Start date changed from estimate of Jan 2024 to Jan 1, 2025 · Site details revised at 2 of 2 sitesv2 Show 3 more changesShow less
    • Primary and study completion dates: Jun 2025 to Jun 2026
    • Start date changed from estimate of Jan 2024 to Jan 1, 2025
    • Site details revised at 2 of 2 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
During the COVID-19 pandemic, testing primarily relied on the use of nasopharyngeal swabs to detect the SARS-CoV-2 virus, responsible for the disease. However, this technique has several limitations, including the variable quality of swabs, its invasive nature, and arbitrariness in the choice of the number of cycles. Furthermore, it does not allow for the detection of viral proteins. To overcome these limitations, researchers developed the eBAM-CoV test, patented for the detection of viral proteins in the exhaled air of COVID-19 patients. This portable device provides an immediate assessment of the "viral load" with both quantitative and qualitative results, showing promise for early virus detection. The researchers hypothesize that the eBAM-CoV test is likely to exhibit a satisfactory concordance with the reference RT-PCR test in the detection of COVID-19, especially among symptomatic patients or closed contacts.
Trial Details
NCT Number NCT06099795
Lead Sponsor Centre Hospitalier Universitaire de Nīmes
Collaborators: University of Nimes, brains' laboratory sas, FRANCE
Conditions SARS-CoV-2 Infection, COVID-19, Coronavirus
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov